Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 951 - 1000 of 1864 results
- Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack.
- Dendritic/tumor fusion cell-based vaccination against cancer.
- Identification of toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma.
- Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma.
- Trastuzumab-Resistant HER2-Driven Breast Cancer Cells Are Sensitive to Epigallocatechin-3 Gallate.
- Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.
- Targeting CCL2 with Systemic Delivery of Neutralizing Antibodies Induces Prostate Cancer Tumor Regression In vivo.
- The Multikinase Inhibitor Sorafenib Potentiates TRAIL Lethality in Human Leukemia Cells in Association with Mcl-1 and cFLIPL Down-regulation.
- Local administration of interleukin-11 ameliorates intestinal radiation injury in rats.
- Phage Display Derived Human Monoclonal Antibodies Isolated by Binding to the Surface of Live Primary Breast Cancer Cells Recognize GRP78.
- Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non-Small-Cell Lung Cancer.
- A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer.
- Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.
- Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines.
- The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.
- The Pilot Study of Anti-Tumor Effects versus Immunosuppression of Staphylococcal Enterotoxin C.
- Novel Decapeptides that Bind Avidly and Deliver Radioisotope to Colon Cancer Cells.
- Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application.
- An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy.
- Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck.
- Dual role of CCL3/CCR1 in oral squamous cell carcinoma: Implications in tumor metastasis and local host defense.
- Potential for molecular targeted therapy of HER-2/neu for invasive bladder cancer: examination of gene amplification by fluorescence in situ hybridization.
- Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma.
- Bleomycin Induced Pulmonary Fibrosis is Attenuated by a Monoclonal Antibody Targeting HER2.
- Ab therapy of AML: native anti-CD33 Ab and drug conjugates.
- Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer.
- Feasibility and Cardiac Safety of Pegylated Liposomal Doxorubicin plus Trastuzumab in Heavily Pretreated Patients with Recurrent HER2-Overexpressing Metastatic Breast Cancer.
- Engineering secretable forms of chaperones for immune modulation and vaccine development.
- Effects of ultrasound on apoptosis induced by anti-CD20 antibody in CD20-positive B lymphoma cells.
- A Phase II Study of Cetuximab (Erbitux(R)) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer.
- Antitumor activities of TEM8-Fc: an engineered antibody-like molecule targeting tumor endothelial marker 8.
- Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose.
- The Chemokine Receptor CXCR4 Strongly Promotes Neuroblastoma Primary Tumour and Metastatic Growth, but not Invasion.
- Preparation and Characterization of Paclitaxel-loaded PLGA Nanoparticles Coated with Cationic SM5-1 Single-chain Antibody.
- Resiquimod and other immune response modifiers as vaccine adjuvants.
- Roles of the novel interleukin-12-associated cytokine, interleukin-23, in the regulation of T-cell-mediated immunity.
- Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency.
- Expression and purification of the cancer antigen SSX2: A potential cancer vaccine.
- Recent advances in the development of oncolytic HSV-1 vectors: 'Arming' of HSV-1 vectors and application of bacterial artificial chromosome technology for their construction.
- GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers.
- Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.
- Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma.
- Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC.
- Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF).
- Cyclosporin a inhibits HTLV-I tax expression and shows anti-tumor effects in combination with VP-16.
- Transfer of suppressor of cytokine signaling 3 by an oncolytic adenovirus induces potential antitumor activities in hepatocellular carcinoma.
- Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
- Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer.
- Phase II Study of Ketoconazole Plus Granulocyte-Macrophage Colony-Stimulating Factor for Prostate Cancer: Effect of Extent of Disease on Outcome.
- A Phase II Trial of Bortezomib and Prednisone for Castration Resistant Metastatic Prostate Cancer.